The research progress of bladder preservation strategies for high-risk non-muscle invasive bladder cancer
10.3760/cma.j.cn112330-20240802-00349
- VernacularTitle:高危非肌层浸润性膀胱癌的保膀胱策略研究进展
- Author:
Xiangyu WU
1
;
Zihan ZHAO
1
;
Xin YANG
1
;
Xiang DU
1
;
Hongqian GUO
1
;
Rong YANG
1
Author Information
1. 南京大学医学院附属鼓楼医院泌尿外科，南京 210008
- Publication Type:Journal Article
- Keywords:
Bladder cancer;
Non-muscle invasive bladder cancer;
Bladder preservation treatment;
Immunotherapy
- From:
Chinese Journal of Urology
2025;46(4):307-311
- CountryChina
- Language:Chinese
-
Abstract:
High-risk non-muscle invasive bladder cancer (HR-NMIBC) is associated with a higher risk of recurrence and progression. The standard treatment involves intravesical Bacillus Calmette-Guérin (BCG) instillation following transurethral resection of the bladder cancer. However, in cases of BCG unresponsiveness, radical cystectomy is typically recommended. Due to the high complication rates and significant impact on quality of life associated with this procedure, bladder-preserving treatment (BPT) strategies have emerged as an alternative. This review summarizes recent advances in BPT, including combined chemoradiotherapy, immune checkpoint inhibitors, targeted therapies, localized precision treatments, and novel immunomodulators. With ongoing technological and therapeutic innovations, BPT has become an effective alternative for patients who are unable or unwilling to undergo surgery, reshaping the treatment landscape of HR-NMIBC.
